ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment from FDA
ANN ARBOR, MI – February 11, 2016 – ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced [...]
ONL Therapeutics to Present at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting
ANN ARBOR, MI – October 29, 2015 – ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced [...]
ONL Therapeutics Announces Formation of Scientific Advisory Board
Renowned Retinal Disease Thought Leaders to Help Guide Development of Novel Vision Protection Technology in Age-Related Macular Degeneration (AMD) and Retinal Detachment ANN ARBOR, MI – [...]
ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases
Company Promotes Lead Development Compound and Expands Clinical Program to Include Dry and Wet Age-Related Macular Degeneration (AMD) ANN ARBOR, MI – June 15, 2015 – ONL Therapeutics, [...]
ONL Therapeutics to Present at Upcoming Investor and Scientific Conferences
ANN ARBOR, MI – March 12, 2015 – ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced [...]
ONL Therapeutics Announces Management Team Additions
Company Strengthens Leadership by Naming Chief Science Officer, Chief Medical Officer and SVP of Operations ANN ARBOR, MI – December 3, 2014 – ONL Therapeutics, Inc., a biopharmaceutical company [...]
ONL Therapeutics Receives Phase II SBIR Grant from National Eye Institute for Development of Novel Retinal Disease Treatment
ANN ARBOR, MI – November 12, 2014 – ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced that the [...]